Press Releases Avenue Therapeutics, Inc.

Equities

ATXI

US05360L4032

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
6.2 ^USD	-29.34%		-36.41%	-48.65%

Mar. 18	Avenue Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 22	Avenue Therapeutics, Inc. Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in A Translational Model of Absence Epilepsy	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Avenue Therapeutics Announces Reverse Stock Split	Apr. 24	AQ
Avenue Therapeutics to Host Virtual Key Opinion Leader Event on April 4, 2024	Mar. 26	AQ
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024	Mar. 25	AQ
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights	Mar. 18	AQ
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq	Mar. 15	AQ
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting	Mar. 11	AQ
Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy	Feb. 22	AQ
Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference	Jan. 11	AQ
Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds	Jan. 05	AQ
Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol	Jan. 04	AQ
Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy	Jan. 03	AQ
Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)	Jan. 02	AQ
Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting	Dec. 04	AQ
Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting	Dec. 01	AQ
Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights	Nov. 13	AQ
Avenue Therapeutics Announces Closing of $5.0 Million Public Offering	Nov. 02	AQ
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering	23-10-31	AQ
Avenue Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference	23-09-05	AQ
Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights	23-08-10	AQ
Avenue Therapeutics Announces High Potency and Full Efficacy in a Model of Generalized Seizures for its Novel GABA-A Receptor Potentiator, BAER-101, Supporting Phase 2 Clinical Study	23-08-01	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Avenue Therapeutics, Inc.

Equities

ATXI

US05360L4032

Press Releases

Filters